SCHEMBL11943599

SCHEMBL11943599

CCOCCCNc1c(N2CC3CC2CN3S(=O)(=O)c2cccs2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
RAB9A P51151 2/20 0.34
POLB P06746 1/20 0.33
SLC2A1 P11166 1/20 0.33
SLC2A3 P11169 1/20 0.33
MAPT P10636 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 2/20 0.32
MAPK1 P28482 1/20 0.32
GAA P10253 2/20 0.31
NPC1 O15118 2/20 0.31
TSHR P16473 1/20 0.31
USP2 O75604 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943619 0.89 KDM4E (0.37) KDM4ESMN1; SMN2RAB9ASLC2A1SLC2A3
SCHEMBL11943613 0.88 KDM4E (0.38) KDM4ESMN1; SMN2RAB9APOLBSLC2A1
SCHEMBL11943597 0.85 MAPT (0.36) KDM4ESMN1; SMN2RAB9ASLC2A1SLC2A3
SCHEMBL11943596 0.84 GCKR (0.41) KDM4ESMN1; SMN2RAB9APOLBMAPT
SCHEMBL11943876 0.81 SLC2A1 (0.36) KDM4ESMN1; SMN2RAB9APOLBSLC2A1
SCHEMBL11943610 0.76 MAPT (0.49) KDM4ERAB9AMAPTALDH1A1MAPK1
SCHEMBL11943612 0.73 MAPT (0.41) KDM4ESMN1; SMN2RAB9APOLBMAPT
SCHEMBL13304479 0.73 SMN1; SMN2 (0.55) KDM4ESMN1; SMN2RAB9APOLBMAPT
SCHEMBL11943532 0.72 MAPT (0.43) KDM4ESMN1; SMN2RAB9APOLBMAPT
SCHEMBL11943541 0.72 MAPT (0.43) KDM4ESMN1; SMN2RAB9APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA KDM4E 1548/4885SMN1; SMN2 3911/4885RAB9A 4688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.